While there are promising preliminary results among breast cancer and NSCLC patients treated with the IGF1R inhibitor Dalotuzumab,[74] according to our results, the subgroup of male patients with NSCLC appears to benefit the most of such a treatment. Here, IGF1R is linked to non-small cell lung carcinoma.